China Lung Cancer Screening Market Surges Toward US$ 1.29 Bn by 2032, Driven by Rising Health Awareness

Overview of the China Lung Cancer Screening Market

The China lung cancer screening market is poised for robust expansion, with projected revenue reaching US$ 1,295.5 million by 2032, up from US$ 616.2 million in 2025. This growth reflects a strong CAGR of 11.2% between 2025 and 2032, underscoring an evolving healthcare landscape that prioritizes early detection and preventative strategies. As lung cancer continues to be the leading cause of cancer-related deaths in China-responsible for over 700,000 deaths annually-government policy, technological advancements, and public health campaigns are collectively intensifying screening efforts to combat this deadly disease.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/35427

Among various modalities, Low-Dose Computed Tomography (LDCT) remains the most effective screening method, expected to hold over 71.4% of market share by 2025. Non-small Cell Lung Cancer (NSCLC) dominates the cancer-type segment due to the increasing incidence of adenocarcinoma, particularly in urban and high-pollution regions. Geographically, Shandong leads the market, driven by high disease prevalence, well-developed healthcare infrastructure, and aggressive public health initiatives aimed at increasing early detection through LDCT.

✦ Key Highlights from the Report

✦ LDCT scan expected to account for 71.4% of the market share in 2025 due to its early-stage detection advantages.
✦ Shandong province is projected to dominate the regional market due to strong uptake of opportunistic LDCT screening.
✦ Government-backed initiatives and NCSP inclusion are driving the growth of lung cancer screening across China.
✦ NSCLC is the leading cancer type owing to increasing adenocarcinoma rates linked to pollution and indoor fumes.
✦ AI-based diagnostics are gaining traction and improving diagnostic accuracy and screening rates.
✦ False-positive rates and uneven regional participation remain major challenges to sustained market expansion.

📊 Market Segmentation

The China lung cancer screening market is segmented by cancer type, diagnosis method, and end-user demographics. Based on cancer type, NSCLC accounts for the majority share-projected at 82.4% in 2025-due to increasing diagnosis of adenocarcinomas, which are easier to detect using LDCT. SCLC, while less prevalent, is on the rise in smoking-heavy provinces like Hebei.

From a diagnostic perspective, the LDCT segment dominates, benefiting from cost-effectiveness and integration into public health initiatives. Meanwhile, chest X-rays, while less sensitive, remain relevant in primary check-ups and awareness campaigns. By end-user, government hospitals, urban health centers, and county-level facilities represent key consumer groups, with rural access slowly expanding through mobile CT units and AI-based teleradiology systems.

🌐 Regional Insights

Shandong leads the Chinese lung cancer screening market with above-average incidence and mortality rates and strong integration of LDCT programs into public healthcare systems. The province exemplifies aggressive adoption of early screening, supported by national guidelines.

In Sichuan, despite relatively strong urban participation, spatial disparities affect access in rural and minority-dominated areas. Public health surveys suggest a need for increased investment in transportation, local screening capacity, and digital health navigation.

Jiangsu province stands out for its high screening uptake and early implementation of the National Lung Cancer Screening framework. Structural enhancements like scan scheduling, media outreach, and diagnostic acceleration have positioned Jiangsu as a model for comprehensive screening infrastructure.

📈 Market Drivers

Government efforts have been pivotal in expanding lung cancer screening services. From 2020 to 2022, China's National Cancer Screening Program (NCSP) added lung cancer screening as a key focus area, providing LDCT for high-risk populations. Public insurance initiatives, local guideline customization, and wide-scale education campaigns are further accelerating participation rates. These policies are especially tailored to reflect China-specific demographic data, including high rates of non-smoker adenocarcinoma and a rapidly aging population.

❌ Market Restraints

Despite the rapid growth of screening services, low participation remains a critical bottleneck. Studies have shown that less than half of invited high-risk individuals actually undergo LDCT scans. Factors such as follow-up costs, work-related constraints, distrust in medical systems, and low health literacy all contribute to this hesitancy. Moreover, high false-positive rates-reaching up to 68.8% in national programs-lead to unnecessary interventions and patient anxiety, further hindering sustained screening engagement.

🔎 Market Opportunities

AI technology represents a promising solution to many of the market's pain points. AI-assisted image analysis is improving diagnostic accuracy, reducing false positives, and alleviating pressure on radiologists. Pioneering efforts like Hangzhou Yitu's algorithm in Sichuan and CMixNet's performance with over 90% specificity offer scalable models for national adoption. These tools are particularly impactful in identifying early-stage adenocarcinomas among non-smoking women, shifting the diagnostic landscape from late-stage to curable early detection.

Do You Have Any Query Or Specific Requirement? Request Customization of Report: https://www.persistencemarketresearch.com/request-customization/35427

Frequently Asked Questions (FAQs)

What is the Projected Growth Rate of the China Lung Cancer Screening Market?
How Big is the China Lung Cancer Screening Market in 2025 and 2032?
Which Region is Estimated to Dominate the Industry through the Forecast Period?
Who are the Key Players in the Global Market for Lung Cancer Screening?
What is the Market Forecast for Lung Cancer Screening in China by 2032?

💼 Company Insights

• GE Healthcare
• Siemens Healthineers
• Canon Medical Systems
• Shanghai United Imaging Healthcare
• Neusoft Medical Systems
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Hangzhou Yitu Healthcare Technology Co., Ltd.
• Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.

Recent Developments:

In April 2025, researchers from Guangzhou Institute of Respiratory Disease highlighted the importance of screening non-smokers with LDCT, showing results comparable to those in smokers.

In January 2025, Sichuan University researchers found only 23.88% of urban residents in Sichuan had sufficient lung cancer awareness, revealing significant gaps in public education.

Conclusion

The China lung cancer screening market stands at the confluence of urgent public health need and rapid technological advancement. With lung cancer continuing to pose a significant health burden, national and provincial authorities are increasingly prioritizing early detection through LDCT and AI-enhanced diagnostics. While regional disparities and compliance issues remain, the market shows promising signs of evolution, underpinned by robust policy support and cutting-edge innovations. The forecasted CAGR of 11.2% from 2025 to 2032 indicates strong momentum, offering compelling opportunities for healthcare providers, investors, and technology innovators aiming to reshape lung cancer outcomes in China.

Like & Follow Us:

https://www.linkedin.com/newsletters/medtech-hub-7281980855462297600/
https://www.linkedin.com/newsletters/the-semicon-update-7282654083763621888/
https://www.linkedin.com/newsletters/smarttech-industries-7281982219085099008/
https://www.youtube.com/@InsightfulAnalytics-q7v/videos
https://www.facebook.com/profile.php
https://www.instagram.com/persistenceinsights/
https://x.com/pmrinsights
https://in.pinterest.com/1puhytovpaceo8p5m1u6dmz30n1iub/pmr/

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web:
https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.